Accessibility Menu
Zomedica logo

Zomedica(NYSEMKT) ZOM

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-89%
5 Year-86%
1 Year+111%
1 Month-12%
N/A
Zomedica last closing stock price
MetricPriceDate
Last closeUSD 0.082026-07-28
Zomedica stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.77%USD 0.092026-07-21
1 month-12.26%USD 0.102026-06-26
3 month-14.35%USD 0.102026-04-29
Year to date-17.51%USD 0.102025-12-31
1 year+111.42%USD 0.042025-07-28
3 year-59.74%USD 0.212023-07-28
5 year-86.24%USD 0.612021-07-29
Since inception-89.28%USD 0.832016-07-29

Zomedica Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$34.33M

Net Income (TTM)

-$22.58M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Mar 13, 2025

ZOM News

veterinarian works with dog

Why Shares of Zomedica Were Zooming Monday

James HalleyMar 20, 2023
People crowding around a computer.

2 Meme Stocks That Are Still Down 50% Since February 2021

David Jagielski, CPAAug 20, 2022
Frustrated people looking at a laptop.

2 Meme Stocks Investors Should Avoid at All Costs

David Jagielski, CPAApr 1, 2022
Veterinarian with a dog

Zomedica Stock Jumped Today. Is It a Buy?

Keith SpeightsFeb 28, 2022
Veterinarian with woman and dog

Why Zomedica Stock Is Soaring Today

Keith SpeightsFeb 28, 2022
vetcare

Why Zomedica Stock Soared 72.4% This Week

James HalleyFeb 17, 2022
zomedica

Why Shares of Zomedica Corp. Dropped 22.5% in December

James HalleyJan 4, 2022
People playing video games in a cafe.

3 Rookie Mistakes to Avoid Making in the Stock Market

David Jagielski, CPADec 29, 2021
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zomedica

Zomedica Corp. is a veterinary healthcare enterprise focused on developing innovative products for companion animals. The company specializes in point-of-care diagnostic tools and therapeutic solutions for various veterinary needs.

Products and Services
  • TRUFORMA platform for point-of-care diagnostics
  • PulseVet system for musculoskeletal conditions in animals
  • Collaborative agreements for cancer detection and pathogen detection
Growth Outlook
  • Recent quarterly revenue of $8.8 million shows strong demand for products
  • Partnerships with Celsee, Inc. and Seraph Biosciences enhance product offerings
  • Market expansion opportunities in the growing veterinary diagnostics sector
Financial Highlights
  • Trailing twelve months revenue of $38.5 million indicates growth potential
  • Current ratio of 7.01 suggests strong liquidity position
  • Cash and short-term investments total $47.5 million, providing financial stability
Zomedica Corp. is positioned to capitalize on the increasing demand for veterinary healthcare solutions. The company's innovative products, such as the TRUFORMA platform, are designed to meet the specific needs of veterinarians, enhancing diagnostic capabilities for companion animals. Recent financial performance indicates a positive trajectory, with significant revenue growth and a robust liquidity position. Collaborative agreements with other companies further strengthen Zomedica's market presence and product offerings, making it a noteworthy player in the veterinary healthcare industry.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

141

CEO

Larry C. Heaton, II

Website

www.zomedica.com

Headquarters

Ann Arbor, MI 48108, US

ZOM Financials

Key Financial Metrics (TTM)

Gross Margin

66.29%

Operating Margin

-71.97%

Net Income Margin

-65.78%

Return on Equity

-19.16%

Return on Capital

-72.65%

Return on Assets

-18.58%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$22.76M

Operating Income

-$24.71M

EBITDA

-$12.98M

Operating Cash Flow

-$16.26M

Capital Expenditure

$0.00

Free Cash Flow

-$16.26M

Cash & ST Invst.

$47.51M

Total Debt

$715.00K

Zomedica Performance Analysis

Zomedica annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 18,930,000358.0%
20232023-12-31USD 25,186,00033.0%
20242024-12-31USD 27,285,0008.3%
20252025-12-31USD 32,030,00017.4%
Zomedica sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-307.1%
Q32025-09-3016.2%
Q42025-12-3129.4%
Q12026-03-31-16.0%
Zomedica annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.02-9.4%
20232023-12-31USD -0.04102.3%
20242024-12-31USD -0.0536.1%
20252025-12-31USD -0.0874.3%
Zomedica sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3085.7%
Q32025-09-30N/A
Q42025-12-31200.0%
Q12026-03-31-146.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

$8.80M

+35.4%

Gross Profit

$5.48M

+24.4%

Gross Margin

62.33%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

144

N/A

Net Income

-$4.53M

+92.9%

EBITDA

$1.89M

-14.6%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

$47.51M

-25.3%

Total Debt

$715.00K

+6.7%

Accounts Receivable

$4.80M

+126.0%

Inventory

$5.88M

+9.6%

Long Term Debt

$0.00

N/A

Short Term Debt

$715.00K

+6.7%

Return on Assets

-18.58%

N/A

Return on Invested Capital

-21.87%

N/A

Free Cash Flow

-$5.26M

+20.9%

Operating Cash Flow

-$5.26M

+20.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OPTNOptiNose, Inc.
$9.60+0.00%
ZYNEZynerba Pharmaceuticals, Inc.
$1.30+2.36%
UPXIUpexi, Inc.
$0.88+3.85%
AADIAadi Bioscience, Inc.
$2.05-2.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.22-0.01%
NOKNokia
$8.93-0.03%
JBLUJetBlue Airways
$6.00+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.15-0.01%

Questions About ZOM

What is the current price of Zomedica?

Zomedica is trading at N/A per share.

What is the 52-week range for Zomedica?

Over the past 52 weeks, Zomedica has traded between N/A and N/A.

How much debt does Zomedica have?

As of the most recent reporting period, Zomedica reported total debt of $2.01M.

How much cash does Zomedica have on hand?

Zomedica reported $9.37M in cash and cash equivalents in its most recent financial results.

What is Zomedica’s dividend yield?

Zomedica does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services